RT Generic
T1 Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19
A1 Riera-Mestre, Antoni
A1 Iriarte, Adriana
A1 Moreno, Manuela
A1 Del Castillo, Raul
A1 López-Wolf, Daniel
K1 Hereditary hemorrhagic telangiectasia
K1 Rare diseases
K1 Angiogenesis
K1 Coronavirus disease 2019 (COVID-19)
K1 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
K1 Telangiectasia Hemorrágica Hereditaria
K1 Enfermedades Raras
K1 Neovascularización Patológica
AB Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal-dominant disease characterized by pathologic angiogenesis that provokes vascular overgrowth. The evidence about the influence of Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in patients with rare diseases is scarce. We aimed to know the prevalence of coronavirus disease 2019 (COVID-19) in HHT patients. The HHT pathogenic angiogenesis and endothelial injury in COVID-19 are discussed using data from RiHHTa (Computerized Registry of Hereditary Hemorrhagic Telangiectasia) registry. RiHHTa is an open, multicenter, prospective, observational registry including adult patients with HHT. A 27-item survey that captured clinical data of admitted HHT patients for COVID-19 was distributed to all RiHHTa investigators from June 8th to June 24th 2020. Only one out of 1177 HHT patients was admitted for COVID-19 pneumonia. She is a 74 years-old woman with a pathogenic variant in ACVRL1 gene. Her clinical course did not involve mechanical ventilation or worsening epistaxis, and she was successfully discharged after two weeks. The endothelial damage and the consequent angiogenic process in COVID-19 patients deserve further investigation.
PB Springer
SN 0969-6970
YR 2020
FD 2020-10-14
LK http://hdl.handle.net/10668/3347
UL http://hdl.handle.net/10668/3347
LA en
NO Riera-Mestre A, Iriarte A, Moreno M, Del Castillo R, López-Wolf D. Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19. Angiogenesis. 2021;24(1):13-15.
DS RISalud
RD Apr 17, 2025